te Glenmark Pharma inks settlement pact with Pfizer for cancer drug | Zee Business

Glenmark Pharma inks settlement pact with Pfizer for cancer drug

Shares of of the drug maker were trading 1.54 per cent up at Rs 417.9 apiece on BSE.

Glenmark Pharma inks settlement pact with Pfizer for cancer drug
According to IQVIATM sales data for the 12-month period ending September 2022, the Inlyta tablets (1 mg and 5 mg) achieved annual sales of around USD 644.5 million. (Representative image from Reuters)

Glenmark Pharmaceuticals on Tuesday said it has entered into a settlement agreement with Pfizer Inc regarding a cancer treatment drug.

The Mumbai-based drug maker and its US-based unit have inked a settlement pact with drug major Pfizer Inc for Axitinib Tablets (1 mg and 5 mg).

Glenmark's product is the generic version of Pfizer's Inlyta tablets, used to treat kidney cancer.

TRENDING NOW

According to IQVIATM sales data for the 12-month period ending September 2022, the Inlyta tablets (1 mg and 5 mg) achieved annual sales of around USD 644.5 million.

Glenmark said its current portfolio consists of 177 products authorised for distribution in the US marketplace and 47 abbreviated new drug applications (ANDA's) are pending for approval with the US Food and Drug Administration.

Shares of of the drug maker were trading 1.54 per cent up at Rs 417.9 apiece on BSE. 

Reported By: PTI
Written By: PTI
Updated: Tue, Nov 22, 2022
01:51 pm
PTI
RELATED NEWS
Glenmark inks distribution, licensing pacts with Cosmo for acne treatment ointment Glenmark inks distribution, licensing pacts with Cosmo for acne treatment ointment
Glenmark gets USFDA nod for generic Tacrolimus ointment Glenmark gets USFDA nod for generic Tacrolimus ointment
Glenmark Pharma Q1 Results: Net profit falls 18% to Rs 173.13 crore Glenmark Pharma Q1 Results: Net profit falls 18% to Rs 173.13 crore

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x